Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | IL18 | Q14116 | 1/20 | 0.53 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.50 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.49 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.49 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.49 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.48 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20132396 | 0.91 | EGLN2 (0.49) | EGLN2MAPTLMNAMEN1KMT2A | |
| SCHEMBL20132311 | 0.90 | CA1 (0.51) | EGLN2MAPTLMNAMEN1KMT2A | |
| SCHEMBL13055402 | 0.86 | CYP17A1 (0.59) | PTPN11CYP17A1PSMB8NAMPTALDH1A1 | |
| SCHEMBL3557455 | 0.85 | PLAU (0.56) | EGLN2MAPTLMNAMEN1KMT2A | |
| SCHEMBL5528365 | 0.85 | PTPN11 (0.52) | EGLN2MEN1KMT2AKDM4ERAB9A | |
| SCHEMBL3560409 | 0.84 | PLAU (0.51) | EGLN2MAPTMEN1KMT2ARAB9A | |
| SCHEMBL8052509 | 0.84 | PTPN11 (0.53) | EGLN2MAPTLMNAMEN1KMT2A | |
| SCHEMBL15540186 | 0.84 | EGLN2 (0.45) | EGLN2MAPTLMNAMEN1KMT2A | |
| SCHEMBL254714 | 0.83 | PTPN11 (0.51) | EGLN2PTPN11CYP17A1PSMB8NAMPT | |
| SCHEMBL2088691 | 0.82 | PGR (0.62) | MAPTLMNAMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062407-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250381278-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2025-12-18 | — | — | US | disclosed |
| US-12486278-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2025-12-02 | — | — | US | disclosed |
| EP-3474901-B1 | CLEAVABLE TETRAZINE USED IN BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B V (NL) | 2025-08-06 | — | — | EP | disclosed |
| EP-4577211-A2 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | Wake Forest University Health Sciences (US) | 2025-07-02 | — | — | EP | disclosed |
| US-20250011316-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2025-01-09 | — | — | US | disclosed |
| US-12186405-B2 | Cleavable tetrazine used in bio-orthogonal drug activation | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2025-01-07 | — | — | US | disclosed |
| US-20240092788-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2024-03-21 | — | — | US | disclosed |
| WO-2024044744-A2 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044744-A2 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2002-12-19 | — | — | US | disclosed |
| US-20020173507-A1 | Urea compounds and methods of uses | AMGEN INC. | 2002-11-21 | — | — | US | disclosed |
| US-6392083-B2 | REACTING A CYANOBENZYLAMINE WITH AN ACID SELECTED FROM HYDROCHLORIC ACID, SULFURIC ACID, ACETIC ACID, TRIFLUROACETIC ACID AND PROPIONIC ACID TO FORM A SALT HAVING HIGH BULK DENSITY | SHOWA DENKO K.K. (JP) | 2002-05-21 | — | — | US | disclosed |
| WO-2002014311-A2 | UREA COMPOUNDS AND METHODS OF USES | AMGEN INC. (US) | 2002-02-21 | — | — | WO | disclosed |
| US-20010049453-A1 | Process for producing salts of cyanobenzylamines | SHOWA DENKO K.K. | 2001-12-06 | — | — | US | disclosed |
| EP-1151989-A1 | PROCESS FOR PRODUCING SALT OF CYANOBENZYLAMINE OR DERIVATIVE | Showa Denko K.K. (JP) | 2001-11-07 | — | — | EP | disclosed |
| US-6100398-A | Transition metal-catalyzed process for preparing N-aryl amine compounds | YALE UNIVERSITY (US) | 2000-08-08 | — | — | US | disclosed |
| US-5106951-A | Antineoplastic anthracyline agents intercalated with two aromatic side chains or an oligopeptide and covalently attached to an antibody | NEORX CORPORATION (US) | 1992-04-21 | — | — | US | disclosed |
| EP-0471765-A1 | POLYESTER CHAIN-EXTENDED VINYL ETHER URETHANE OLIGOMERS. | ALLIED SIGNAL INC (US) | 1992-02-26 | — | — | EP | disclosed |
| EP-0329184-A2 | Antimers and antimeric conjugation | NEORX CORPORATION (US) | 1989-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486278-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | EGLN2 2400/4885MAPT 3549/4885LMNA 3425/4885 |
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | EGLN2 2178/4885MAPT 1437/4885LMNA 2067/4885 |
| US-20020173507-A1 | Urea compounds and methods of uses | SLC14A1, UMPS, BAX | EGLN2 801/4885MAPT 1801/4885LMNA 1241/4885 |
| US-20260062407-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | PRDX1, PRDX3, PRDX2 | EGLN2 349/4885MAPT 4676/4885LMNA 2939/4885 |
| US-20240092788-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | EGLN2 2400/4885MAPT 3549/4885LMNA 3425/4885 |
| US-20010049453-A1 | Process for producing salts of cyanobenzylamines | MMAB, BLVRB, SLC6A12 | EGLN2 1622/4885MAPT 2222/4885LMNA 2372/4885 |
| US-20250011316-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | PRDX1, PRDX2, PRDX6 | EGLN2 162/4885MAPT 4743/4885LMNA 2798/4885 |
| US-12186405-B2 | Cleavable tetrazine used in bio-orthogonal drug activation | KIT, TPSB2, BTD | EGLN2 3230/4885MAPT 2761/4885LMNA 1516/4885 |
| US-20250381278-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | PRDX1, PRDX2, PRDX6 | EGLN2 145/4885MAPT 4754/4885LMNA 2786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.